Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCL…

Memorial Sloan Kettering Cancer Center

A. Schram

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal

Year in Review 2024 - Targeted Therapy for NSCLC

Nebraska Oncology Society

J. Murray

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

An Update on Lung Cancer Targeted Therapies: The Evolution of Person…

University of Miami Sylvester Comprehensive Cancer Center

E. Rodriguez

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

WCLC 2024 Review: FLAURA2 - Tumor Burden, Outcomes, and TP53 Associa…

ecancer

E. Felip